Scholarly Open Access Journals In Pharmacogenomics|OMICS International|Translational Medicine

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scholarly Open Access Journals In Pharmacogenomics

Scholarly open access journals have emerged as an alternative to traditional subscription journals. Open access scholarly journals are available online to the reader without financial, legal, or technical barriers. Scholarly open access journals are journals which are respected for the extensive research and information they provide about the point. The research often possesses refereed meaning that it is reviewed by other scientists who are knowledgeable about the theme of the article. Scholarly open access journals cite their sources using references or bibliographies. OMICS Group International has 700+ peer-reviewed journals and organizes 3000+ International Scientific Conferences worldwide. Apart from providing a free access to articles to everyone, it also extends support to other scholarly journals in the peer-review process, production, and distribution. All the articles published in OMICS Group journals are peer reviewed and published only on adhering to the norms. Upon acceptance, the articles will be immediately and permanently free for everyone to read and download. Pharmacogenomics (PGx) is the study of genetic variation as it relates to drug response. PGx studies, consisting of testing individuals for multiple variants in drug metabolism enzyme (DME) and transporter genes, are increasing in significance as personalized medicine becomes a reality in standard practice. Technologies that are fast, accurate, cost-effective, and have broad marker coverage are required to support the growing number of PGx studies being conducted. Advances in personalized medicine have led to an increase in pharmacogenomics studies that involve testing individuals for drug metabolism enzyme and transporter gene polymorphisms implicated in drug response. As a consequence, there is a growing demand for affordable, easy to use technologies with fast sample-to-results workflows that can accommodate testing customizable sets of target gene variants and a changeable number of samples. Additionally, data analysis tools are needed to facilitate translation of an individual’s genetic information to their diploid content of gene-level star allele haplotypes, which can be correlated with drug metabolism enzyme phenotypes.Pharmacogenomics studies typically use genotyping and copy number analysis to understand the impact of genetic variation on drug, metabolism, drug efficacy, and adverse drug effects. As pharmacogenomics becomes more widespread, there is a need for simple, streamlined workflow solutions to accomplish studies on varying numbers of samples and target genes. (Toinette Hartshorne, Ferrier Le, Jordan Lang, Harrison Leong, Kathleen Hayashibara, Dominique Dewolf and Elliot Shelton, A High-throughput Real-time PCR Approach to Pharmacogenomics Studies)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2021